| Year |
Citation |
Score |
| 2019 |
Takada M, Smyth LA, Hix JM, Corner SM, O'Reilly S, Kiupel M, Yuzbasiyan-Gurkan V. Development of an Orthotopic Intrasplenic Xenograft Mouse Model of Canine Histiocytic Sarcoma and Its Use in Evaluating the Efficacy of Treatment with Dasatinib. Comparative Medicine. PMID 30717820 DOI: 10.30802/Aalas-Cm-18-000065 |
0.35 |
|
| 2019 |
Yang Y, Yuzbasiyan-Gurkan V, Tepe JJ. Abstract 4729: Targeting c-MYCdegradation as a novel therapeutic strategy for osteosarcoma: Studies in canine and human osteosarcoma cells Cancer Research. 79: 4729-4729. DOI: 10.1158/1538-7445.Am2019-4729 |
0.36 |
|
| 2018 |
Takada M, Hix JML, Corner S, Schall PZ, Kiupel M, Yuzbasiyan-Gurkan V. Targeting MEK in a translational model of histiocytic sarcoma. Molecular Cancer Therapeutics. PMID 30135215 DOI: 10.1158/1535-7163.Mct-17-1273 |
0.36 |
|
| 2018 |
Yang Y, Yuzbasiyan-Gurkan V. Abstract 2949: Synergistic effects of tyrosine kinase inhibitors and conventional chemotherapeutics on canine and human osteosarcoma cells Cancer Research. 78: 2949-2949. DOI: 10.1158/1538-7445.Am2018-2949 |
0.351 |
|
| 2018 |
Moll GM, Yuzbasiyan-Gurkan V. Abstract 2667: Patient-derived lymphoma cell lines and high-throughput screening enable identification of potential cytotoxic therapeutic agents for dogs and cats with lymphoma Cancer Research. 78: 2667-2667. DOI: 10.1158/1538-7445.Am2018-2667 |
0.349 |
|
| 2018 |
Takada M, Smyth L, Yuzbasiyan-Gurkan V. Abstract 2166: Dasatinib displays antitumor efficacy in an orthotopic xenograft mouse model of histiocytic sarcoma Cancer Research. 78: 2166-2166. DOI: 10.1158/1538-7445.Am2018-2166 |
0.323 |
|
| 2017 |
Thaiwong T, Sirivisoot S, Takada M, Yuzbasiyan-Gurkan V, Kiupel M. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese Mountain Dogs. Veterinary and Comparative Oncology. 16: 220-228. PMID 28929581 DOI: 10.1111/Vco.12357 |
0.319 |
|
| 2017 |
Parys M, Kruger JM, Yuzbasiyan-Gurkan V. Evaluation of immunomodulatory properties of feline mesenchymal stem cells. Stem Cells and Development. PMID 28181858 DOI: 10.1089/Scd.2016.0041 |
0.305 |
|
| 2017 |
Corner S, Parys M, Moresco A, Yuzbasiyan-Gurkan V, Agnew D. Abstract TMEM-020: OVARIAN ADENOCARCINOMA IN JAGUARS (PANTHERA ONCA): A NATURALLY-OCCURRING MODEL OF HUMAN INHERITED OVARIAN CANCER? Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-020 |
0.323 |
|
| 2017 |
Yang Y, Yuzbasiyan-Gurkan V. Abstract 4032: Synergistic effects of Bortezomib and JQ1 for human and canine osteosarcoma treatments Cancer Research. 77: 4032-4032. DOI: 10.1158/1538-7445.Am2017-4032 |
0.369 |
|
| 2017 |
Takada M, Yang Y, Piegols H, Saavedra PV, Tang C, Amstutz P, Yuzbasiyan-Gurkan V. Abstract 3921: Detection of circulating tumor cells in osteosarcoma: A validation study using a translational model Cancer Research. 77: 3921-3921. DOI: 10.1158/1538-7445.Am2017-3921 |
0.362 |
|
| 2015 |
Yang Y, Takada M, Yuzbasiyan-Gurkan V. Abstract B46: Evaluation of JQ1 as a cytotoxic agent in canine sarcoma cell lines Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-B46 |
0.336 |
|
| 2015 |
Yang Y, Yuzbasiyan-Gurkan V. Abstract 1749: Bortezomib and JQ1 hold promise for human and canine osteosarcoma Cancer Research. 75: 1749-1749. DOI: 10.1158/1538-7445.Am2015-1749 |
0.345 |
|
| 2014 |
Takada M, Parys M, Gregory-Bryson E, Yuzbasiyan-Gurkan V. Abstract 3931: A novel canine histiocytic sarcoma cell line provides a potential path to effective treatments with relevance for translational and comparative studies in humans Cancer Research. 74: 3931-3931. DOI: 10.1158/1538-7445.Am2014-3931 |
0.373 |
|
| 2014 |
Yang Y, Bartczak E, Yuzbasiyan-Gurkan V. Abstract 1752: Search for effective therapies for canine and human osteosarcoma using novel therapeutic agents Cancer Research. 74: 1752-1752. DOI: 10.1158/1538-7445.Am2014-1752 |
0.337 |
|
| 2013 |
Hayes S, Yuzbasiyan-Gurkan V, Gregory-Bryson E, Kiupel M. Classification of canine nonangiogenic, nonlymphogenic, gastrointestinal sarcomas based on microscopic, immunohistochemical, and molecular characteristics. Veterinary Pathology. 50: 779-88. PMID 23456969 DOI: 10.1177/0300985813478211 |
0.327 |
|
| 2013 |
Yang Y, Yuzbasiyan-Gurkan V. Abstract 4910: The search for the stem cells of human and canine osteosarcoma: evaluation of stemness markers and sarcosphere formation. Cancer Research. 73: 4910-4910. DOI: 10.1158/1538-7445.Am2013-4910 |
0.368 |
|
| 2012 |
Dervisis N, Klahn SL, Kiupel M, Parys M, Gregory-Bryson E, Yuzbasiyan-Gurkan V. Localized and disseminated histiocytic sarcoma complex: A canine model Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-5092 |
0.612 |
|
| 2012 |
Thaiwong T, Kiupel M, Yuzbasiyan-Gurkan V. Abstract 13: Expression of mutant c-KIT isoforms in fibroblasts causes tumorigenic transformation Cancer Research. 72: 13-13. DOI: 10.1158/1538-7445.Am2012-13 |
0.386 |
|
| 2010 |
Gregory-Bryson E, Bartlett E, Kiupel M, Hayes S, Yuzbasiyan-Gurkan V. Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. Bmc Cancer. 10: 559. PMID 20950418 DOI: 10.1186/1471-2407-10-559 |
0.367 |
|
| 2010 |
Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406). Experimental Hematology. 38: 782-91. PMID 20685234 DOI: 10.1016/J.Exphem.2010.05.004 |
0.319 |
|
| 2010 |
Hadzijusufovic E, Peter B, Herrmann H, Schuch K, Thaiwong T, Yuzbasiyan-Gurkan V, Rülicke T, Pickl W, Willmann M, Valent P. Establishment of a Novel Canine Mastocytoma Cell Line, NI-1: a Model for Studying Resistance Against KIT Tyrosine Kinase Inhibitors In Canine Neoplastic Mast Cells Blood. 116: 4936-4936. DOI: 10.1182/Blood.V116.21.4936.4936 |
0.327 |
|
| 2010 |
Dervisis NG, Parys M, Wenker A, Venta P, Kitchell BE, Yuzbasiyan-Gurkan V. Abstract 2661: Evaluation of genetic variability of cytochrome P-450 members in the canine preclinical model Cancer Research. 70: 2661-2661. DOI: 10.1158/1538-7445.Am10-2661 |
0.644 |
|
| 2008 |
Neupane M, Chang CC, Kiupel M, Yuzbasiyan-Gurkan V. Isolation and characterization of canine adipose-derived mesenchymal stem cells. Tissue Engineering. Part A. 14: 1007-15. PMID 19230125 DOI: 10.1089/Ten.Tea.2007.0207 |
0.699 |
|
| 2008 |
Webster JD, Yuzbasiyan-Gurkan V, Thamm DH, Hamilton E, Kiupel M. Evaluation of prognostic markers for canine mast cell tumors treated with vinblastine and prednisone. Bmc Veterinary Research. 4: 32. PMID 18700956 DOI: 10.1186/1746-6148-4-32 |
0.326 |
|
| 2007 |
Webster JD, Yuzbasiyan-Gurkan V, Trosko JE, Chang CC, Kiupel M. Expression of the embryonic transcription factor Oct4 in canine neoplasms: a potential marker for stem cell subpopulations in neoplasia. Veterinary Pathology. 44: 893-900. PMID 18039902 DOI: 10.1354/Vp.44-6-893 |
0.366 |
|
| 2007 |
Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells. Experimental Hematology. 35: 1510-21. PMID 17681669 DOI: 10.1016/J.Exphem.2007.06.005 |
0.32 |
|
| 2007 |
Webster JD, Yuzbasiyan-Gurkan V, Miller RA, Kaneene JB, Kiupel M. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication. Veterinary Pathology. 44: 298-308. PMID 17491070 DOI: 10.1354/Vp.44-3-298 |
0.384 |
|
| 2006 |
Webster JD, Yuzbasiyan-Gurkan V, Kaneene JB, Miller R, Resau JH, Kiupel M. The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia (New York, N.Y.). 8: 104-11. PMID 16611403 DOI: 10.1593/Neo.05622 |
0.371 |
|
| 2006 |
Webster JD, Kiupel M, Yuzbasiyan-Gurkan V. Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. Bmc Cancer. 6: 85. PMID 16579858 DOI: 10.1186/1471-2407-6-85 |
0.363 |
|
| 2004 |
Kiupel M, Webster JD, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V. The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors. Veterinary Pathology. 41: 371-7. PMID 15232137 DOI: 10.1354/Vp.41-4-371 |
0.307 |
|
| 2004 |
Webster JD, Kiupel M, Kaneene JB, Miller R, Yuzbasiyan-Gurkan V. Erratum: The use of KIT and tryptase expression patterns as prognostic tools for canine cutaneous mast cell tumors (Veterinary Pathology (2004) 41 (371-377)) Veterinary Pathology. 41. DOI: 10.1354/Vp.41-5-543 |
0.324 |
|
| 2002 |
Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs. Veterinary Pathology. 39: 529-35. PMID 12243462 DOI: 10.1354/Vp.39-5-529 |
0.709 |
|
| 2002 |
Ding Q, Bramble L, Yuzbasiyan-Gurkan V, Bell T, Meek K. DNA-PKcs mutations in dogs and horses: allele frequency and association with neoplasia. Gene. 283: 263-9. PMID 11867233 DOI: 10.1016/S0378-1119(01)00880-0 |
0.315 |
|
| 2001 |
Schmutz SM, Moker JS, Yuzbasiyan-Gurkan V, Zemke D, Sampson J, Lingaas F, Dunner S, Dolf G. DCT and EDNRB map to DogMap linkage group L07. Animal Genetics. 32: 321. PMID 11683724 DOI: 10.1046/J.1365-2052.2001.0730D.X |
0.66 |
|
| 2001 |
Zemke D, Yamini B, Yuzbasiyan-Gurkan V. Characterization of an undifferentiated malignancy as a mast cell tumor using mutation analysis in the proto-oncogene c-KIT. Journal of Veterinary Diagnostic Investigation : Official Publication of the American Association of Veterinary Laboratory Diagnosticians, Inc. 13: 341-5. PMID 11478608 DOI: 10.1177/104063870101300411 |
0.709 |
|
| 2000 |
Venta PJ, Li J, Yuzbasiyan-Gurkan V, Brewer GJ, Schall WD. Mutation causing von Willebrand's disease in Scottish Terriers. Journal of Veterinary Internal Medicine / American College of Veterinary Internal Medicine. 14: 10-9. PMID 10668811 DOI: 10.1892/0891-6640(2000)014<0010:Mcvwdi>2.3.Co;2 |
0.315 |
|
| 1999 |
Zemke D, Yuzbasiyan-Gurkan V. A single nucleotide polymorphism and a (GA)n microsatellite in intron 6 of the canine endothelin receptor B (EDNRB) gene. Animal Genetics. 30: 390. PMID 10582292 DOI: 10.1046/J.1365-2052.1999.00526-9.X |
0.669 |
|
| Show low-probability matches. |